An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolaemia

Interventions

DRUG: alirocumab SAR236553 (REGN727)
DRUG: statins
DRUG: ezetimibe
DRUG: cholestyramine
DRUG: fenofibrate
DRUG: omega-3 fatty acids
DRUG: nicotinic acid

Sponsor

Sanofi

Collaborators

[object Object]